** Shares of Janux Therapeutics JANX.O rise 67.5% to $67.34 premarket
** Data from early-stage trial shows all 16 patients with a type of prostate cancer that used co's experimental drug JANX007 achieved declines in levels of prostate-specific antigens
** Drug also had "well-tolerated safety profile" and "maximum tolerable dose has not yet been reached"
** Co selects 2 once-weekly dose regimens when expanding early-stage trial based on results
** BTIG analyst Justin Zelin said investor concerns were expectations may have been too high ahead of the results, but JANX's data exceeded expectations and was "unprecedented"
** Brokerage raises PT to Street-high of $100 from $82
** 12 brokerages rate the stock "buy" or higher, 1 "hold"; their median PT is $70 - LSEG
** As of last close, stock had risen 274.5% YTD
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。